AGRX Agile Therapeutics Inc.

+0.02  (+2%)
Previous Close 0.9
Open 0.91
Price To Book 1.37
Market Cap 31499947
Shares 34,377,329
Volume 399,389
Short Ratio
Av. Daily Volume 402,708

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued 2013. Further CRL issued December 22, 2017. Resubmission due 1H 2019.
Contraceptive patch

Latest News

  1. AGRX: Positive Results for Twirla® Adhesion Study; NDA Resubmission in 2Q19
  2. Agile Therapeutics, Inc. Announces that Twirla® Meets Primary Endpoint in Comparative Wear Study and Demonstrates Non-Inferior Adhesion to Xulane®
  3. Agile Therapeutics to Present at the 2019 BIO CEO and Investor Conference
  4. AGRX: Twirla® Adhesion Study Underway; NDA Resubmission in 2Q19…
  5. The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA
  6. Agile Therapeutics, Inc. Provides Regulatory Update and Reiterates Cash Guidance
  7. Factors of Influence in 2019, Key Indicators and Opportunity within Halozyme Therapeutics, Capricor Therapeutics, Appian, Yext, Agile Therapeutics, and Corbus Pharmaceuticals — New Research Emphasizes Economic Growth
  8. Agile Therapeutics to Present at Biotech Showcase 2019
  9. Agile Therapeutics, Inc. Meets With FDA on Comparative Wear Study of Twirla® and Xulane®
  10. Agile Therapeutics Inc (NASDAQ:AGRX): Are Analysts Optimistic?
  11. AGRX: Awaiting Details of Adhesion Study for Twirla®…
  12. Agile Therapeutics: 3Q Earnings Snapshot
  13. Agile Therapeutics Gets a Path Forward for Twirla, Analysts Review and Target
  14. Today’s Research Reports on Stocks to Watch: Auris Medical Holding and Agile Therapeutics
  15. AGRX: FDA Provides Path to NDA Resubmission for Twirla®…
  16. Today's Research Reports on Trending Tickers: Agile Therapeutics and Horizon Pharma

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19607275
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 19590442
  3. 8-K - Current report 19586296
  4. 8-K - Current report 19536545
  5. 424B5 - Prospectus [Rule 424(b)(5)] 19536543
  6. 8-K - Current report 19520439
  7. 8-K - Current report 19512218
  8. 8-K - Current report 19505982
  9. 8-K - Current report 181233710
  10. EFFECT - Notice of Effectiveness 181185871